Artivion Inc. Set to Showcase Innovations at Two Investor Conferences

Artivion, Inc. (NYSE: AORT), a prominent player in cardiac and vascular surgery with a focus on aortic diseases, is gearing up to engage with investors at two notable conferences later this month. These events are an excellent opportunity for Artivion to demonstrate its commitment to advancing medical technology in the realm of cardiovascular health.

Conference Participation

Scheduled for June 17, 2025, Artivion's management team will first present at the Truist Securities MedTech Conference. This event will take place at the InterContinental Boston Hotel, and Artivion's presentation is set to commence at 8:00 a.m. ET. For those unable to attend in person, or for investors interested in revisiting the session, a live webcast will be available via Artivion's official website. An archived recording will remain accessible on the Investors page for 90 days post-event, ensuring all stakeholders have a chance to engage with the material discussed.

In addition to the MedTech Conference, Artivion will also partake in the Citizens Medical Devices and Healthcare Services Forum on the same day. However, this event will follow a different format, and no webcast will be available for this session. This dual appearance reflects Artivion's strategic communications with investors, highlighting its innovative approaches and addressing the complexities faced by medical professionals in treating aortic disease.

About Artivion, Inc.

Headquartered in suburban Atlanta, Georgia, Artivion is dedicated to developing elegant, straightforward solutions to the intricate challenges encountered by cardiac and vascular surgeons. Its product portfolio includes:

- Aortic stent grafts
- Surgical sealants
- On-X mechanical heart valves
- Implantable cardiac and vascular human tissues

Artivion's offerings are designed with the primary aim of enhancing patient care in aortic disease cases, a sector that demands both innovation and precision. As of now, the company’s products are marketed and sold in over 100 countries around the globe, underlining its international presence in the medical device industry.

Looking Ahead

Artivion continues to lead with a vision that emphasizes accessibility and innovation, addressing critical health issues through advanced medical technologies. The upcoming conferences provide an ideal platform not only to engage with current and potential investors but also to shed light on the company's R&D initiatives and future directions. With a robust approach to cardiac health solutions, Artivion remains poised to make significant contributions to global healthcare.

For additional insights into Artivion’s products and upcoming events, please visit their official website at www.artivion.com. This commitment to transparency and investor engagement exemplifies the company's dedication to both the medical community and the patients they serve.

Conclusion

In conclusion, Artivion's participation in these conferences is a testament to its dedication to advancing medical practices in cardiac and vascular surgery. Stakeholders and medical professionals alike will benefit from the insights shared at these events, marking a pivotal moment for those interested in cutting-edge innovations in the treatment of aortic diseases.